Leprosy Relapse: A Retrospective Study on Epidemiologic, Clinical, and Therapeutic Aspects at a Brazilian Referral Center

Int J Infect Dis. 2022 May:118:44-51. doi: 10.1016/j.ijid.2022.01.009. Epub 2022 Jan 10.

Abstract

Objectives: We aimed to characterize the profile of patients diagnosed with leprosy relapse and understand the influence of different multidrug therapy (MDT) treatments and initial disease presentation.

Methods: This retrospective study included patients diagnosed with leprosy relapse at a referral center in Brazil from 2013 to 2018. We analyzed their clinico-epidemiologic characteristics, laboratory data, and bacilloscopic tests. Survival analysis was used to determine the time elapsed until relapse according to the previous treatment and clinical forms of the disease.

Results: A total of 126 cases of relapse were analyzed, which comprised 11.89% (126/1059) of the cases. The median time elapsed until a relapse was 10 years, and most patients had previously undergone 12 doses of MDT (40.48%; 51/126). Undergoing 24 doses of MDT was associated with a better prognosis regarding relapse over time compared with 6 or 12 doses of MDT therapy. Most cases of relapse were classified as multibacillary (96.03%; 121/126).

Conclusion: The incidence of relapse was greater than observed in other studies. The high percentage of multibacillary patients who had negative bacillary indices demonstrated that the bacillary index cannot be considered to be an essential criterion for relapse, especially concerning making an early diagnosis.

Keywords: Leprosy; Relapse; Treatment; Treatment failure.

MeSH terms

  • Brazil / epidemiology
  • Chronic Disease
  • Drug Therapy, Combination
  • Humans
  • Leprostatic Agents* / therapeutic use
  • Leprosy* / drug therapy
  • Recurrence
  • Referral and Consultation
  • Retrospective Studies

Substances

  • Leprostatic Agents